Navigation Links
IR BioSciences Announces Promising Data from Study of Its Compound,Homspera

Data Suggests Homspera Shows Promise As an Adjuvant for Vaccines against Avian Flu and Other Viruses

SCOTTSDALE, Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- IR BioSciences Holdings, Inc. announced today that preliminary data from its influenza vaccine adjuvant study being performed in conjunction with GenPhar Inc. indicates Homspera elevates host immune responsiveness above that induced by vaccine alone system. These results are from an ongoing study, and are a strong indication that Homspera may demonstrate adjuvant capabilities, and thus be capable of augmenting host immune system responsiveness to vaccines for diseases such as pandemic avian influenza, seasonal influenza, and perhaps others for which vaccines exist or are under development.

Adjuvants are common additions to vaccine formulations, as they enable the vaccine to induce a strong immune reaction in vaccinated individuals, helping to ensure adequate immunological protection.

The Homspera studies, being carried out by GenPhar, examine the impact of vaccination with pieces of influenza viruses (a current H5N1 "avian influenza" strain and from the 1918 Spanish Influenza virus). A fear of many scientists and public health officials is that the current avian influenza endemic to Southeast Asia may mutate sufficiently to become more easily transmitted among humans, yet maintain its highly pathogenic nature. Such an event, centered on the virus currently exhibiting mortality in infected humans of approximately 50%, can trigger a rapid global spread of highly pathogenic virus with disastrous consequences.

Vaccines against avian influenza are not available in volumes needed to inoculate a significant percentage of the world's population. Similarly, the most effective prophylactic or therapeutic drug, oseltamivir (Tamiflu(R), Roche), is reportedly not being stockpiled in amounts adequate to provide protection to the at-risk population.
'"/>




Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:11/18/2014)... 2014  AgeneBio, a pharmaceutical company developing innovative ... brain function, today announced that the Company,s founder ... PhD, has received the Society for Neuroscience,s Mika ... years, Dr. Gallagher,s research at Johns Hopkins and ... has led to advancements in the field of ...
(Date:11/17/2014)... Nov. 17, 2014 Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that Jane ... Development, will participate in a live Google Hangout session ... discussing the latest progress in stem cell-based therapies for ... Hangout session is scheduled for Tuesday, November 18, 2014, ...
(Date:11/17/2014)... , November 17, 2014 ... Boston on 20 November   ... discovery and development company, is pleased to announce that ... as one of ten top projects in neuroscience by ... Grau will present an overview of the programme ...
Breaking Medicine Technology:AgeneBio Founder and Chief Scientific Officer Receives Society for Neuroscience's Mika Salpeter Lifetime Achievement Award 2AgeneBio Founder and Chief Scientific Officer Receives Society for Neuroscience's Mika Salpeter Lifetime Achievement Award 3Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury 2Heptares First-in-Class Selective Muscarinic Agonists Chosen as one of top Neuroscience Projects to Watch 2
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ("AcelRx"), a ... innovative therapies for the treatment of acute or breakthrough pain, ... ended December 31, 2010. Net loss for the ... common share, compared with a net loss of $3.7 million, ...
... 23, 2011 Actavis Group, an international generic pharmaceuticals ... the US Food & Drug Administration to market Valacyclovir ... 500mg and 1 gram, the generic equivalent of Valtrex® ... for the 12 months ending December 31, 2010, according ...
Cached Medicine Technology:AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 2AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 3AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 4AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 5AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 6Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2
(Date:11/18/2014)... (PRWEB) November 18, 2014 Financing ... focused on innovative financing for international development, has ... Directors. Membership includes six Directors: Mr. John Skibiak ... Bent of the Millennium Challenge Corporation, Mr. Pape ... Total Impact Advisors, Mr. Aron Betru of Financing ...
(Date:11/18/2014)... TN (PRWEB) November 18, 2014 ... company for pharmaceutical, nutraceutical, dietary supplements and more, ... awarded NSF International’s Good Manufacturing Practices (GMP) Registration ... Earning GMP registration from NSF International verifies the ... safety and quality compliance requirements of its clients ...
(Date:11/18/2014)... Hispanic women who,ve had at least five children are much ... than those who,ve had fewer children or none, a new ... Aggarwal of Wake Forest School of Medicine analyzed data on ... York City and San Diego. About 12 percent of them ... type of heart trouble called ventricular diastolic dysfunction -- an ...
(Date:11/18/2014)... Until recently, insect-transmitted Chagas disease was found mainly in Latin ... to the United States over the past few years. ... bite of the "kissing bug," which feeds on the faces ... that common bedbugs might be carriers as well. "We,ve ... Our next step is to determine whether they are, or ...
(Date:11/17/2014)... Home Care Assistance – Halton/Peel Region ( ... senior care, is advising seniors to make sure they ... the immune system and makes it more difficult to ... a greater concern at this time of year, when ... year’s influenza season (November to March), over 5,200 adults ...
Breaking Medicine News(10 mins):Health News:Financing for Development Corp. (F4D) Announces Board of Directors 2Health News:Financing for Development Corp. (F4D) Announces Board of Directors 3Health News:Financing for Development Corp. (F4D) Announces Board of Directors 4Health News:A+ Secure Packaging, LLC Earns NSF International Good Manufacturing Practices (GMP) Registration for Dietary Supplements and Certification for Sport 2Health News:Certain Heart Dysfunction More Likely in Hispanic Women With Many Kids: Study 2Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 2Health News:Bedbugs Could Be Potential New Source of Tropical Disease in U.S. 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Encourages Seniors to Get Annual Flu Shot 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Encourages Seniors to Get Annual Flu Shot 3
... trials show some success in helping children , FRIDAY, ... effective in treating juvenile rheumatoid arthritis, according to studies ... (ACR) meeting in Boston. , One study found that ... rheumatoid arthritis, may be a well-tolerated treatment for children ...
... researchers have shown that an immunosuppressive drug used in ... patients with systemic lupus erythematosus (SLE). SLE results in ... joints and kidneys. Its cause is unknown. The findings ... American College of Rheumatology in Boston. , Our findings ...
... Rural/Metro,Corporation (Nasdaq: RURL ) announced it will ... 30, 2007 and fiscal 2007 fourth quarter,and 12 months ... on November,14, 2007. In conjunction, the Company will host ... at 9 a.m. (Pacific)/ 11 a.m.,(Eastern). Also on ...
... Hooper Holmes,Inc. (Amex: HH ), a leading ... the third quarter ended September 30,2007. Third quarter ... the corresponding period of 2006. The Company recorded a ... million, or $(0.16) per share,compared to a net loss ...
... The Signature,Wounds of Operation Iraqi Freedom and ... Veterans for America,s,"Trends in Treatment of ... trends adversely affecting servicemembers and veterans,suffering from ... - traumatic,brain injury (TBI) and psychological traumas., ...
... N.C., EXTON, Pa. and SAN DIEGO, Nov. 9 ... US,provider of oncology equipment sales and service, announced ... with Radiology Oncology Systems, Inc.,(ROS), an oncology and ... Inc., a US provider of oncology equipment service,and ...
Cached Medicine News:Health News:Drugs Can Ease Juvenile Rheumatoid Arthritis 2Health News:Rural/Metro to Host Conference Call to Discuss Results for First Quarter Fiscal 2008 and Fourth Quarter/Fiscal 2007 Year-End 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 2Health News:Hooper Holmes Announces Third Quarter 2007 Results 3Health News:Hooper Holmes Announces Third Quarter 2007 Results 4Health News:Hooper Holmes Announces Third Quarter 2007 Results 5Health News:Hooper Holmes Announces Third Quarter 2007 Results 6Health News:Hooper Holmes Announces Third Quarter 2007 Results 7Health News:Report Release: Veterans for America Finds Care for PTSD and TBI Inadequate 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3
For the quantitative determination of Alkaline Phosphatase in serum. Linearity: 800 IU/L at 37C. P-nitrophenyl phosphate substrate....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: 3.5 - 7.0 mg/dL. Available with calibrator and number of test 125....
For determination of uric acid in serum, plasma or urine. For Hitachi 704 / 911. Available with Calibrator: Trucal U and controls: Trulab N and Trulab P....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
Medicine Products: